Update Course Rewind: Management of Appendicitis 2022

Space: StayCurrentMD Playlist: Update Course Rewinds Author: Stay Current Published: 2023-05-25

Expert / Speaker

Stay Current
General Surgery
0 Views
0 Likes
0 Shares
0 Comments

Timestops

00:00:41
Overview of the three main topics: non-perforated, perforated, and non-surgical treatment.
Overview of the three main topics: non-perforated, perforated, and non-surgical treatment.
00:01:23
Distinction between perforated and non-perforated appendicitis is introduced. Gangrenous vs Supportive Discussion
Distinction between perforated and non-perforated appendicitis is introduced. Gangrenous vs Supportive Discussion
00:02:30
Clinical standpoint on classifying appendicitis: Perforated vs Non-perforated definition. Impact on same-day discharge.
Clinical standpoint on classifying appendicitis: Perforated vs Non-perforated definition. Impact on same-day discharge.
00:03:12
Discussion of same-day discharge for non-perforated appendicitis and success rates.
Discussion of same-day discharge for non-perforated appendicitis and success rates.
00:08:01
Criteria for discharging patients after IV antibiotics; focusing on patient tolerance and clinical decision-making.
Criteria for discharging patients after IV antibiotics; focusing on patient tolerance and clinical decision-making.
00:09:07
Concern raised about early discharge (less than 24 hours) and discussion on abscess rates and treating patients as 'healthy'.
Concern raised about early discharge (less than 24 hours) and discussion on abscess rates and treating patients as 'healthy'.
00:12:01
Patient case presented to evaluate eligibility for non-operative management.
Patient case presented to evaluate eligibility for non-operative management.
00:12:33
Criteria for Non-operative management: symptom duration, appendiceal diameter, absence of abscess/phlegmon/fecalith, and white blood cell count. Reference to KOTA trial.
Criteria for Non-operative management: symptom duration, appendiceal diameter, absence of abscess/phlegmon/fecalith, and white blood cell count. Reference to KOTA trial.
00:13:54
Discussion of non-surgical treatment effectiveness and target failure rates in multi-center trials.
Discussion of non-surgical treatment effectiveness and target failure rates in multi-center trials.

Topic overview

Appendicitis is one of the most common conditions seen by pediatric surgeons but still has many controversies in management.

This topic was discussed in the 10th annual Update Course in Pediatric Surgery 2022, with Drs. Meera Kotagal, Tolu Oyetunji, Shawn St. Peter, and Whit Holcomb we discuss the updates about treatment and management in appendicitis.

Here is a summary of the most important aspects of the talk. If you want to see the whole video go to the Live event channel.

Articles discussed:

An evidence-based definition for perforated appendicitis derived from a prospective randomized trial

Computed Tomography Utilization for the Diagnosis of Acute Appendicitis in Children Decreases With a Diagnostic Algorithm

Single daily dosing ceftriaxone and metronidazole vs standard triple antibiotic regimen for perforated appendicitis in children: a prospective randomized trial

Same-Day Discharge for Nonperforated Appendicitis in Children: An Updated Institutional Protocol

Irrigation Versus Suction Alone During Laparoscopic Appendectomy for Perforated Appendicitis: A Prospective Randomized Trial

Decreased resource utilization since initiation of institutional clinical pathway for care of children with perforated appendicitis

Safety of a new protocol decreasing antibiotic utilization after laparoscopic appendectomy for perforated appendicitis in children: A prospective observational study

Association of Nonoperative Management Using Antibiotic Therapy vs Laparoscopic Appendectomy With Treatment Success and Disability Days in Children With Uncomplicated Appendicitis

 

Intended audience: Healthcare professionals and clinicians.

Transcript

Speaker: Stay Current

Click "Show Transcript" to view the full transcription (10240 characters)

Comments

Loading comments...